We are live on ! Find out more
ADAP

Adaptimmune Therapeutics
ADAP

Delisted

ADAP was delisted on the 27th of October, 2025.

Back to rankings

49 hedge funds and large institutions have $219M invested in Adaptimmune Therapeutics in 2017 Q1 according to their latest regulatory filings, with 16 funds opening new positions, 13 increasing their positions, 7 reducing their positions, and 7 closing their positions.

New
Increased
Maintained
Reduced
Closed

129% more first-time investments, than exits

New positions opened: 16 | Existing positions closed: 7

86% more repeat investments, than reductions

Existing positions increased: 13 | Existing positions reduced: 7

81% more capital invested

Capital invested by funds: $121M → $219M (+$97.8M)

23% more funds holding

Funds holding: 40 → 49 (+9)

2.34% more ownership

Funds ownership: 7.02% → 9.36% (+2.3%)

Holders
49
Holders Change
+9
Holders Change %
+22.5%
% of All Funds
1.22%
Holding in Top 10
1
Holding in Top 10 Change
+1
Holding in Top 10 Change %
% of All Funds
0.02%
New
16
Increased
13
Reduced
7
Closed
7
Calls
$3K
Puts
–
Net Calls
+$3K
Net Calls Change
+$3K

Top Buyers

Rank Fund Capital Flow
1
Capital World Investors
Capital World Investors
California
+$10.1M
2
NMC
NEA Management Company
Maryland
+$9.38M
3
HIM
Hillhouse Investment Management
Cayman Islands
+$5.21M
4
O
OrbiMed
New York
+$5.21M
5
Axa
Axa
France
+$3.94M

Top Sellers

Rank Fund Capital Flow
1
Fidelity Investments
Fidelity Investments
Massachusetts
-$3.43M
2
AFM
Anson Funds Management
Texas
-$418K
3
IHM
Iguana Healthcare Management
New York
-$405K
4
IBT
International Biotechnology Trust
United Kingdom
-$387K
5
Adage Capital Partners
Adage Capital Partners
Massachusetts
-$219K
Name Holding Trade Value Shares
Change 		Change in
Stake
State Street
26
State Street
Massachusetts
$363K – – –
AA
27
ALPS Advisors
Colorado
$336K -$31.2K -7,128 -10%
CLOS
28
Compagnie Lombard Odier SCmA
Switzerland
$317K – – –
EIM
29
Essex Investment Management
Massachusetts
$225K +$178K +40,772 New
Creative Planning
30
Creative Planning
Kansas
$223K +$43.7K +10,000 +33%
DADC
31
D.A. Davidson & Co
Montana
$205K +$163K +37,337 New
ARTA
32
A.R.T. Advisors
New York
$186K +$148K +33,773 New
PP
33
Paloma Partners
Connecticut
$165K +$131K +30,000 New
MIM
34
Monashee Investment Management
Massachusetts
$138K – – –
VKH
35
Virtu KCG Holdings
New York
$133K +$106K +24,174 New
State of New Jersey Common Pension Fund D
36
State of New Jersey Common Pension Fund D
New Jersey
$132K – – –
RJFSA
37
Raymond James Financial Services Advisors
Florida
$120K +$95.5K +21,827 New
JP Morgan Chase
38
JP Morgan Chase
New York
$113K -$58K -13,253 -39%
PCM
39
Prelude Capital Management
New York
$107K +$85.3K +19,506 New
Geode Capital Management
40
Geode Capital Management
Massachusetts
$92K +$1.84K +420 +3%
NSEDCP
41
NJ State Employees Deferred Compensation Plan
New Jersey
$89K – – –
Zurich Cantonal Bank
42
Zurich Cantonal Bank
Switzerland
$64K -$14.4K -3,285 -22%
GT
43
Glenmede Trust
Pennsylvania
$48K – – –
Morgan Stanley
44
Morgan Stanley
New York
$48K +$37.9K +8,673 New
Wells Fargo
45
Wells Fargo
California
$42K +$27.1K +6,200 +443%
CSS
46
Cubist Systematic Strategies
Connecticut
$7K +$5.25K +1,200 New
OAJ
47
Ogorek Anthony Joseph
New York
$5K – – –
UBS Group
48
UBS Group
Switzerland
$4K -$9 -2 -0.3%
ASN
49
Advisory Services Network
Georgia
$1K +$437 +100 New
AFM
50
Anson Funds Management
Texas
– -$418K -103,282 Closed
1
2
3

ADAP Hedge Fund Activity: Q1 2017 in Review

49 of the 4,018 institutional investors tracked by Wall St. Rank reported a position in Adaptimmune Therapeutics (ADAP) for Q1 2017, worth a combined $219M — up 81% from $121M a quarter earlier.

Buyers outnumbered sellers: 16 funds opened new ADAP positions and 7 closed out — a net gain of 9 holders — while 13 added to existing stakes and 7 trimmed.

The largest buyer was Capital World Investors, adding an estimated $10.1M. The largest seller was Fidelity Investments, cutting an estimated $3.43M.

  • 49 institutional investors held Adaptimmune Therapeutics (ADAP) as of Q1 2017, up from 40 in Q4 2016.
  • Funds reported $219M of Adaptimmune Therapeutics stock for Q1 2017, up 81% quarter-over-quarter.
  • 16 funds opened new Adaptimmune Therapeutics positions in Q1 2017 and 7 closed out, a net change of +9 holders.
  • The largest Adaptimmune Therapeutics buyer in Q1 2017 was Capital World Investors, an estimated $10.1M added.
  • The largest Adaptimmune Therapeutics seller in Q1 2017 was Fidelity Investments, an estimated $3.43M sold.

Based on aggregated 13F filings for Q1 2017.